FASS logotyp
Receptbelagd

Peka på symbolerna och beteckningarna till vänster för en förklaring.

Kontakt

Sök apotek med läkemedlet i lager

Sök lagerstatus

Clindamycin Orifarm

Orifarm Generics AB

Kapsel, hård 300 mg
(vita hårda kapslar med märkningen "CLIN 300" på kapselstommen.)

Linkosamider

Aktiv substans:
ATC-kod: J01FF01
Läkemedel från Orifarm Generics AB omfattas av Läkemedelsförsäkringen.
Vad innebär restanmält läkemedel?
Information om restanmält läkemedel
Vissa förpackningar av Clindamycin Orifarm Kapsel, hård 300 mg är restanmälda hos Läkemedelsverket. Kontrollera lagerstatus för att se om ditt apotek har läkemedlet i lager.

Kontakta ditt apotek eller din läkare om du har frågor.

  • Vad är miljöinformation?

Miljöinformation

Miljöpåverkan

Miljöinformationen för klindamycin är framtagen av företaget GlaxoSmithKline för Duac®

Miljörisk: Risk för miljöpåverkan av klindamycin kan inte uteslutas då ekotoxikologiska data saknas.
Nedbrytning: Det kan inte uteslutas att klindamycin är persistent, då data saknas.
Bioackumulering: Klindamycin har låg potential att bioackumuleras.


Läs mer

Detaljerad miljöinformation

Environmental Risk Classification


Predicted Environmental Concentration (PEC)

PEC is calculated according to the following formula:


PEC (μg/L) = (A*109*(100-R))/(365*P*V*D*100) = 1.37*10-6*A(100-R)


PEC = 0.144 μg/L


Where:

A = 1,049.85 kg (total sold amount API in Sweden year 2020, data from IQVIA). Total volume of Clindamycin phosphate = 79.07 = 66.42 clindamycin free base. Total volume of Clindamycin hydrochloride 983.43 = 904.66 clindamycin free base. Total volume of Clindamycin palmitate hydrochoride = 17.63 = 10.83 clindamycin free base. Total Clindamycin = 66.42 + 983.43 + 10.83 = 1,049.85.

R = 0% removal rate (conservatively, it has been assumed there is no loss by adsorption to sludge particles, by volatilization, hydrolysis or biodegradation).

P = number of inhabitants in Sweden = 10 *106

V (L/day) = volume of wastewater per capita and day = 200 (ECHA default) (Reference 1)

D = factor for dilution of waste water by surface water flow = 10 (ECHA default) (Reference 1)


Predicted No Effect Concentration (PNEC)

Ecotoxicological studies

Green Algae (Pseudokirchneriella subcapitata):

EC50 (inhibition of growth rate) = 4.1 μg/L (OECD 201) (Reference 3)

EC10 = 0.98 μg/L


Water flea (Daphnia magna):

Acute toxicity

No data

NOEC = 1,000,000 μg/L

Chronic toxicity

No data


Fish:

Acute toxicity

No data

Chronic toxicity

No data


Other ecotoxicity data:

Microorganisms in activated sludge:

No data


PNEC cannot be calculated because data is not available for all three (algae, crustacean and fish) of the toxicity endpoints.


Environmental risk classification (PEC/PNEC ratio)

Risk of environmental impact of clindamycin cannot be excluded, since there is not sufficient ecotoxicity data available.


Degradation

Biotic degradation

Ready degradability:

No data


Inherent degradability:

No data


Abiotic degradation

Hydrolysis:

No data


Photolysis:

No data



Justification of chosen degradation phrase:

The phrase “The potential for persistence of Clindamycin is cannot be excluded, due to lack of data” is thus chosen.



Bioaccumulation

Partitioning coefficient:

Log Dowcalc at pH 5 = -1.47 (QSAR) (Reference 4)

Log Dowcalc at pH 7 = 0.38

Log Dowcalc at pH 9 = 1.02


Justification of chosen bioaccumulation phrase:

Since log Kow < 4 at pH 7, the substance has a low potential for bioaccumulation.



Excretion (metabolism)

In an open-label study of 24 patients with moderate-to-severe acne vulgaris, approximately 4 grams of Duac Once Daily 10 mg/g + 30 mg/g Gel was applied once daily for 5 days to the face, upper chest, upper back, and shoulders. Geometric mean maximal plasma clindamycin exposure (Cmax) on Day 5 was 0.961 ng/mL with an AUC∞ of 12.9 ng*hr/mL.


In a maximised percutaneous absorption study the mean plasma clindamycin levels during a four-week dosing period for clindamycin 10 mg/g + benzoyl peroxide 50 mg/g gel were negligible (0.043 % of applied dose). (Reference 2).



PBT/vPvB assessment

Clindamycin does not fulfil the criteria for PBT and/or vPvB


All three properties, i.e. ‘P’, ‘B’ and ‘T’ are required in order to classify a compound as PBT (Reference 1). Clindamycin does not fulfil the criteria for PBT and/or vBvP based on log Dow < 4.



Please, also see Safety data sheets on http://www.msds-gsk.com/ExtMSDSlist.asp



References

  1. ECHA, European Chemicals Agency. 2008 Guidance on information requirements and chemical safety assessment.

  2. Pharmacokinetic properties: Metabolism and Elimination. Summary of Product Characteristics DUAC once Daily 10mg/g and 30mg/g Gel. Stiefel, March 2018.

  3. https://www.amrindustryalliance.org/wp-content/uploads/2018/09/AMR_Industry_Alliance_List-of-Predicted-No-Effect-Concentrations-PNECs.pdf

  4. Instant J Chem Log P and LogD. Sep 2012. Chemaxon Inc.